These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 26877068)
1. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. Shendre A; Brown TM; Liu N; Hill CE; Beasley TM; Nickerson DA; Limdi NA Pharmacotherapy; 2016 Mar; 36(3):263-72. PubMed ID: 26877068 [TBL] [Abstract][Full Text] [Related]
2. Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. Limdi NA; Brown TM; Shendre A; Liu N; Hill CE; Beasley TM Pharmacogenet Genomics; 2017 Oct; 27(10):347-355. PubMed ID: 28806200 [TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219 [TBL] [Abstract][Full Text] [Related]
4. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259 [TBL] [Abstract][Full Text] [Related]
5. Genetic determinants of variability in warfarin response after the dose-titration phase. Iwuchukwu OF; Ramirez AH; Shi Y; Bowton EA; Kawai VK; Schildcrout JS; Roden DM; Denny JC; Stein CM Pharmacogenet Genomics; 2016 Nov; 26(11):510-516. PubMed ID: 27632229 [TBL] [Abstract][Full Text] [Related]
6. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Liang R; Wang C; Zhao H; Huang J; Hu D; Sun Y Thromb Res; 2012 Jul; 130(1):38-44. PubMed ID: 22192158 [TBL] [Abstract][Full Text] [Related]
7. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. Li J; Yang W; Xie Z; Yu K; Chen Y; Cui K BMC Cardiovasc Disord; 2018 May; 18(1):96. PubMed ID: 29776386 [TBL] [Abstract][Full Text] [Related]
8. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Bress A; Patel SR; Perera MA; Campbell RT; Kittles RA; Cavallari LH Pharmacogenomics; 2012 Dec; 13(16):1925-35. PubMed ID: 23215885 [TBL] [Abstract][Full Text] [Related]
9. Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Shendre A; Parmar GM; Dillon C; Beasley TM; Limdi NA Pharmacotherapy; 2018 Jun; 38(6):588-596. PubMed ID: 29393514 [TBL] [Abstract][Full Text] [Related]
11. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Bejarano-Achache I; Levy L; Mlynarsky L; Bialer M; Muszkat M; Caraco Y Clin Ther; 2012 Apr; 34(4):811-23. PubMed ID: 22417713 [TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099 [TBL] [Abstract][Full Text] [Related]
13. Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Yanik MV; Irvin MR; Beasley TM; Jacobson PA; Julian BA; Limdi NA Pharmacotherapy; 2017 Nov; 37(11):1366-1373. PubMed ID: 28949423 [TBL] [Abstract][Full Text] [Related]
14. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893 [TBL] [Abstract][Full Text] [Related]
15. Race influences warfarin dose changes associated with genetic factors. Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874 [TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms. Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728 [TBL] [Abstract][Full Text] [Related]
17. Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array. Liu N; Irvin MR; Zhi D; Patki A; Beasley TM; Nickerson DA; Hill CE; Chen J; Kimmel SE; Limdi NA Pharmacogenomics; 2017 Jul; 18(11):1059-1073. PubMed ID: 28686080 [TBL] [Abstract][Full Text] [Related]
18. Effect of gene polymorphims on the warfarin treatment at initial stage. Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206 [TBL] [Abstract][Full Text] [Related]
19. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Kealey C; Chen Z; Christie J; Thorn CF; Whitehead AS; Price M; Samaha FF; Kimmel SE Pharmacogenomics; 2007 Mar; 8(3):217-25. PubMed ID: 17324110 [TBL] [Abstract][Full Text] [Related]
20. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Ramirez AH; Shi Y; Schildcrout JS; Delaney JT; Xu H; Oetjens MT; Zuvich RL; Basford MA; Bowton E; Jiang M; Speltz P; Zink R; Cowan J; Pulley JM; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC Pharmacogenomics; 2012 Mar; 13(4):407-18. PubMed ID: 22329724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]